Cargando…

Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease

Introduction Despite the use of unfractionated heparin (UFH) or low molecular weight heparin (LMWH), rates of thromboembolic disease, and subsequent morbidity and mortality remain unacceptably high in patients with severe novel coronavirus disease 2019 (COVID-19) disease. Direct oral anticoagulants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wenzler, Eric, Engineer, Monaz H., Yaqoob, Maidah, Benken, Scott T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685067/ https://www.ncbi.nlm.nih.gov/pubmed/33244512 http://dx.doi.org/10.1055/s-0040-1720962

Ejemplares similares

Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy
por: Andrews, Lauren, et al.
Publicado: (2021)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Aftermath of Apixaban: Atypical Anticoagulation Aftereffect
por: Karki, Bhesh, et al.
Publicado: (2022)

Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome
por: Van Meerhaeghe, Tess, et al.
Publicado: (2022)

Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation
por: Martin, Andrew, et al.
Publicado: (2012)

Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
por: Mezue, Kenechukwu, et al.
Publicado: (2017)

Pituitary Apoplexy in the Setting of Oral Anticoagulation Therapy With Apixaban
por: Rivera-Nieves, Yadiel, et al.
Publicado: (2021)

Spontaneous thoracolumbar epidural hematoma in an apixaban anticoagulated patient
por: Theofanopoulos, Andreas, et al.
Publicado: (2021)

Dual Anticoagulation With Warfarin and Apixaban: A Case Report
por: Parker, Kristen, et al.
Publicado: (2022)

An Inconspicuous Offender: Apixaban-Induced Anticoagulant-Related Nephropathy
por: Shaw, Dylan J, et al.
Publicado: (2023)

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Publicado: (2021)

CRITICALLY ILL COVID-19 PATIENTS AND THERAPEUTIC ANTICOAGULATION WITH HEPARIN
por: Vu, Michael, et al.
Publicado: (2022)

Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban
por: DiNicolantonio, James J, et al.
Publicado: (2014)

Adrenal Hemorrhage in a Patient Anticoagulated with Apixaban with Antiphospholipid Syndrome
por: Sanford, Zachary, et al.
Publicado: (2019)

Anticoagulant activity of apixaban can be estimated by multiple regression analysis
por: Unami, Naoko, et al.
Publicado: (2020)

Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis
por: Bharath, Suman Preet, et al.
Publicado: (2023)

COVID-19: ICU delirium management during SARS-CoV-2 pandemic—pharmacological considerations
por: Andrews, Lauren J., et al.
Publicado: (2020)

1142 Critically Ill Children Hospitalized with an Acute Respiratory Viral Infection: Characterizing ICU severity
por: Harwayne-Gidansky, Ilana, et al.
Publicado: (2014)

Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
por: Freyburger, Geneviève, et al.
Publicado: (2015)

Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation
por: Kyriakou, Elias, et al.
Publicado: (2018)

Sustained resolution of anticoagulation related iron deficiency anemia with the use of apixaban
por: Choo, Alex, et al.
Publicado: (2019)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects
por: Ansell, Jack, et al.
Publicado: (2021)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
por: Werth, Sebastian, et al.
Publicado: (2012)

Comparing the Efficacy and Safety of Apixaban Versus Warfarin in Morbidly Obese Patients
por: Alotaibi, Sultan N, et al.
Publicado: (2022)

Acute Febrile Respiratory Illness in the ICU
por: Sandrock, Christian, et al.
Publicado: (2008)

‘Chronomics’ in ICU: circadian aspects of immune response and therapeutic perspectives in the critically ill
por: Papaioannou, Vasilios, et al.
Publicado: (2014)

Critical Analysis of Apixaban Dose Adjustment Criteria
por: Vu, Anh, et al.
Publicado: (2021)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Recurrence of LV Thrombus in a Patient with Severe Ischaemic Cardiomyopathy Anticoagulated with Apixaban
por: Farooqui, Azhar, et al.
Publicado: (2022)

Apixaban: Lack of efficacy: case report
Publicado: (2022)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Respiratory Support in Severely or Critically Ill ICU Patients With COVID-19 in Wuhan, China
por: Hu, Hong-tao, et al.
Publicado: (2020)

Out-of-the-ICU Mobilization in Critically Ill Patients: The Safety of a New Model of Rehabilitation
por: Sasano, Nobuko, et al.
Publicado: (2022)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

Reversibility of Apixaban Anticoagulation with a Four‐Factor Prothrombin Complex Concentrate in Healthy Volunteers
por: Nagalla, S, et al.
Publicado: (2016)

Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation
por: Pillarisetti, Jayasree, et al.
Publicado: (2020)

Tailoring Apixaban in Nanostructured Lipid Carrier Enhancing Its Oral Bioavailability and Anticoagulant Activity
por: Zaky, Mohamed F., et al.
Publicado: (2022)

Response to “Critical Analysis of Apixaban Dose Adjustment Criteria”
por: Mandt, Stephen R., et al.
Publicado: (2022)

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis
por: Lin, Yao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_703gn06imv6j50g7asfgstdc9b